Actuate Therapeutics, Inc. (ACTU) - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Actuate Therapeutics, Inc., a Delaware corporation and emerging growth company, on February 7, 2025. The report announces the scheduling of the Company's first Annual Meeting of Stockholders.
Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses solely on corporate governance events and does not contain financial performance data.
Material Changes
There are no material financial changes reported in this filing. The primary event is the establishment of the Annual Meeting schedule and record date.
Guidance, Outlook, and Corporate Events
- Annual Meeting: The Company will host its first Annual Meeting of Stockholders virtually on May 22, 2025.
- Record Date: The Board of Directors set the record date as March 25, 2025. Stockholders of record on this date are entitled to notice and to vote.
- Proxy Statement: Additional details regarding voting matters and access instructions will be provided in a proxy statement to be filed with the SEC prior to the meeting.
- Stockholder Proposals (Rule 14a-8): Proposals must be received by the close of business on February 21, 2025, to be considered for inclusion in proxy materials.
- Director Nominations: Advance notice for director nominations or other proposals not under Rule 14a-8 must also be provided by the close of business on February 21, 2025.
Key Facts for Investor Verification
- Verify the record date of March 25, 2025, to determine voting eligibility.
- Note the strict deadline of February 21, 2025, for submitting stockholder proposals or director nominations.
- Monitor upcoming filings for the proxy statement containing specific agenda items and virtual meeting access details.
- Confirm the Company's status as an emerging growth company for potential reporting exemptions.